Listing 3 - Actual negotiations

Indication:

Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) Relapsed or refractory , DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL) or follicular lymphoma Grade 3B (FLG3b), in adult patients, after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.

Indication:

Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab)

Indication:

Stage IIB or IIC melanoma following complete resection, monotherapy for the adjuvant treatment of adult patients

Indication:

Psoriasis, moderate to severe plaque

Indication:

Hepatocellular carcinoma (HCC)

Indication:

Atopic dermatitis

Indication:

Symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy

Indication:

Acute Lymphoblastic Leukemia (ALL)

Indication:

Multiple Indications

Indication:

Multiple Indications